Anavex Life Sciences Corp (AVXL)

[falconer66a]

What Anavex Knows.

Missling knows the number. His could be close to Falconer's.

Yes, I posted some quite astonishing revenue and dividends potentials for Anavex Life Sciences Corp., all predicated upon the validity (safety, efficacy) of Anavex 2-73 against Alzheimer’s disease. I did not detail the drug’s applications against any other CNS disease.

Interestingly, no one has posted numbers or information that would invalidate my projections. In fact, there are facts supporting each contention. Of course, rather hazy, given the incomplete state of the drug’s clinical trials; but otherwise plausible. As I mentioned, if my projections are off by an entire order of magnitude (10x too high), Anavex Life Sciences Corp nonetheless will be extremely profitable in coming years.

So, does CEO Dr. Christopher Missling know “the number?” Might he and the other Anavex principals have a more accurate, more likely understanding of future Anavex financials? Please, anyone, post other data and information that could more precisely narrow the projected Anavex financial metrics.

What information is missing that keeps any of us from projecting these metrics with reasonable precision? Not enough human clinical results? I find useful (and satisfactory) the clinical data now from the Australians with Alzheimer’s, and the young women with Rett syndrome. All very positive.

As a biologist who understands cellular physiology and biochemistry, I’m even more impressed with the massive body of very positive murine (rodent) studies and results, first with the conditions being clinically reviewed in humans (Rett syndrome, Parkinson’s Disease Dementia, and Alzheimer’s) but even more so against a diversity of other diseases and conditions. Those are the ones that Missling really knows about.

First, the contention a few years ago by some that murine studies can’t reliably predict human clinical outcomes for the three diseases in human trials is no longer posted. No one, now, says that mice with Rett genes and symptoms can’t reveal human efficacy. The recent Rett results in the six girls demonstrates the efficacy of those murine studies. The same will occur in the other two human trials.

That’s what Missling really knows. His people have been dosing rats with all sorts of diseases and conditions. He knows exactly how Anavex 2-73, Anavex 3-71, Anavex 1-41, Anavex 1066, Anavex 1037 and any other yet undisclosed sigma-1 receptor agonist molecules work against a host of human diseases — not just those in the central nervous system.

For CNS diseases (well, all the others, too), the Anavex molecules work differently from all other drugs. The existing drugs treat the downstream, end-stage pathologies. Anavex sigma-1 receptor agonists fix anomalous, pathogenic processes at their basal start or origin. With that, any or all of the downstream pathological outcomes are obviated. The treated cell works normally. The Anavex drugs restore or promote normalized homeostasis, causing cells to properly respond to maintenance stimuli, without excessive reaction. Homeostasis — homeo = same; stasis = state or condition.

That’s one profound therapeutic outcome in disrupted cells. Another is facilitated, normalized autophagy, “self-eating;” the process by which cells eat up or chemically remove or degrade cellular wastes. Autophagic failure fills cells and tissues with pathogenic wastes (such as the beta-amyloid and tau tangle wastes of Alzheimer’s).

The Anavex molecules also facilitate proper inside the cell signaling and transport of calcium ions, facilitating normalized cell physiology.

It also appears the Anavex molecules can promote or facilitate favorable gene expression, while suppressing aberrant genetic outcomes. Favorable Anavex-facilitated epigenetics.

With all of that, it is understandable and reasonable that the Anavex sigma-1 receptor agonists can fix just a diversity of diseases and conditions, not just those of the central nervous system.

Privately, I’ve diagramed how the Anavex molecules might work against a number of non-CNS diseases. I won’t post any of those here. To do so would simply prompt a bunch of “Ridiculous. Can’t be so!” pronouncements. But, Missling knows. In a year or two, after approval of one or two of the Anavex drugs, revenues will allow for expanded, diverse clinical trials in humans, against a variety of diseases and conditions.

Anavex will be more than a CNS drug company. Many big new things yet to be tested and proven in humans. The unique mechansims of action of the several Anavex drugs will be utilized. No other class of pharmaceuticals will be able to do this. It’s an iceberg, indeed. Missling knows. He has the murine data; he knows the mechanisms of action and how they restore cellular health.

Lastly is the biggest potential therapeutic application of the Anavex drugs. I’ve seen no murine studies on any of this yet, but I’m certain Missling has commissioned post-docs to check out the anti-aging, disease prevention modalities of Anavex sigma-1 receptor agonists in lab rats and mice. Any chance that Anavex drugs might prevent the onset of diseases or geriatric decline before any of those take place? Profound prophylaxis? A significant anti-aging drug? Mechanistically, very possible. Maintain youthful homeostasis, autophagy, and gene expression.